Fragile X syndrome (FXS) is the most common form of inherited intellectual disability, resulting from a CGG repeat expansion in the fragile X mental retardation 1 (FMR1) gene. Here, we report a strategy for CGG repeat correction using CRISPR/Cas9 for targeted deletion in both embryonic stem cells and induced pluripotent stem cells derived from FXS patients. Following gene correction in FXS induced pluripotent stem cells, FMR1 expression was restored and sustained in neural precursor cells and mature neurons. Strikingly, after removal of the CGG repeats, the upstream CpG island of the FMR1 promoter showed extensive demethylation, an open chromatin state, and transcription initiation. These results suggest a silencing maintenance mechanism for the FMR1 promoter that is dependent on the existence of the CGG repeat expansion. Our strategy for deletion of trinucleotide repeats provides further insights into the molecular mechanisms of FXS and future therapies of trinucleotide repeat disorders.
In Brief
Park et al. demonstrate deletion of the extended CGG repeats in fragile Xderived induced pluripotent stem cells. The ablation of the triple repeats caused demethylation of the FMR1 promoter as well as reactivation of the gene both at the mRNA and protein levels that persisted through differentiation into mature neurons.
INTRODUCTION
Fragile X syndrome (FXS) is the most common inherited form of intellectual disability with an incidence in males of one in 3,600, and it is caused by the silencing of the fragile X mental retardation 1 (FMR1) gene located on chromosome X (Crawford et al., 2001; O'Donnell and Warren, 2002; Penagarikano et al., 2007) . The causative mutation in FXS is a triple nucleotide CGG repeat expansion located in the 5 0 -UTR of FMR1 Verkerk et al., 1991) . Although healthy individuals harbor between 5 and 55 copies of the CGG repeats, affected patients harbor more than 200 copies and are considered as having a full mutation (Pearson et al., 2005) . It has been demonstrated that the silencing of FMR1 in patients with a full mutation is correlated with abnormal DNA methylation and epigenetic changes in the CGG repeats (Coffee et al., 2002; Urbach et al., 2010; Eiges et al., 2007; Avitzour et al., 2014; Tabolacci et al., 2008) .
We previously have generated models for FXS in embryonic stem cells (ESCs) (Eiges et al., 2007) and in induced pluripotent stem cells (iPSCs) (Urbach et al., 2010) , and, using these models, we have demonstrated both the temporal silencing of FMR1 during embryonic development and the ability to generate FXS neurons. We also have shown that the demethylating agent 5-azacytidine (5-AzaC) can induce reactivation of FMR1 expression in FXS-iPSCs and partial demethylation of the FMR1 promoter, suggesting a direct effect of methylation on the silencing of FMR1 (Bar-Nur et al., 2012) . However, the interrelationship between the CGG repeats found at the 5 0 -UTR of FMR1 and the silencing of the gene is still obscure. It is also unclear whether a silenced methylated gene promoter could be demethylated upon removal of the downstream CGG repeats, and whether these changes would in turn affect gene expression.
The prokaryotic Type II clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated 9 (Cas9) system, also known as RNA-guided endonucleases (RGENs), acts as an adaptive immune response in bacteria and archaea (Horvath and Barrangou, 2010; Wiedenheft et al., 2012) . During the last few years, this system has been remodeled and adapted for genome editing (Cong et al., 2013; Mali et al., 2013; Cho et al., 2013; Wang et al., 2013) . The Cas9 nuclease (derived from Streptococcus pyogenes) can be guided by a single-guide RNA (sgRNA) that is complementary to the target DNA via Watson-Crick base pairing and via the 5 0 -NGG motif known as the protospacer adjacent motif (PAM) (Jinek et al., 2012) . The guided delivery of the Cas9 nuclease to its target site results in a DNA double-strand break (DSB) 3 bp upstream of the PAM sequence. The introduction of a DSB at a genomic locus increases the occurrence of insertion/deletion mutations or homology-directed recombination (HDR) by cellular repair mechanisms.
Patient-specific iPSCs derived from affected individuals are suggested as a promising therapeutic source to treat and study genetic disorders by correcting the causal mutations. In this work, we utilized the RGEN system to edit the CGG repeats located at the 5 0 -UTR of FMR1. We show that removal of the CGG repeats can induce reactivation of silenced FMR1 gene expression in FXS iPSC systems and their derivatives. Furthermore, we demonstrate complete DNA demethylation of the FMR1 promoter in FXS-edited lines, suggesting that the DNA methylation status of the FMR1 promoter in FXS iPSCs is dependent upon the CGG repeats and is constantly maintained according to the methylation status of the repeats. This study demonstrates that a full mutation of a CGG repeat expansion can be corrected using engineered nucleases in a patient-specific iPSC system without the use of template DNA for correction. This strategy may provide a promising applicable approach in the study of gene and cell therapy for future treatment of FXS and other genetic diseases caused by abnormal trinucleotide repeat expansions.
RESULTS

Sequence Analysis of the 5
0 -UTR within the FMR1 Gene To identify DNA sequences in the FMR1 gene that would enable deletion of the CGG repeats, we determined the sequence of the CGG repeats and their flanking regions (herein termed upstream and downstream of the CGG repeats) in wild-type (WT) and FXS iPSCs and ESCs. We first amplified the 5 0 -UTR from WT cell lines using the primer sets FMR1-F and FMR1-R ( Figure S1A ). In the case of FXS iPSCs and ESCs, we amplified the upstream and downstream regions of the CGG repeats separately, using FMR1-F/FMR1-R1 or FMR1-F1/FMR1-R primers, respectively ( Figure S1A ). This is because conventional PCR methods have difficulty amplifying fully mutated CGG repeats that are more than 200 copies long, which is the case in FXS patients. Indeed, previous reports have indicated that the FXS iPSCs used in this study harbored more than 450 repeats, and the FXS ESCs in this study harbored more than 200 CGG repeats (Gray et al., 2007; Eiges et al., 2007) . Our WT cells showed repeated structures of nine to ten CGG trinucleotides linked with or without a single AGG trinucleotide ( Figure S1B ; Table S1 ). Interestingly, we found that the sequences of the flanking upstream and downstream regions in WT and patient-derived cells were identical ( Figure S1B ). The FMR1 gene resided on the X chromosome and appeared in only one allele in male cells; we thus hypothesized that DSB-induced deletions of the CGG repeats would be resolved by non-homologous end joining (NHEJ) between the sequences flanking the triplet repeats.
RGEN-Induced Mutations within the FMR1 Gene in HEK293T Cells
Next, we generated RGEN composed of the Cas9 nuclease and sgRNA that targeted the end of the upstream sequence of the CGG repeats ( Figure 1A ). To confirm the RGEN genome-editing activities, a T7 endonuclease I (T7E1) assay was performed in HEK293T cells. The RGEN activity was relatively high, inducing mutations with a frequency of 41% at the target site ( Figure 1B) . In additional sequencing analyses, large deleted sequences as well as small insertions and deletions (indels) were found at the RGEN target site ( Figure S1C ). Because off-target mutations may cause undesirable effects when using RGEN systems (Fu et al., 2013; Hsu et al., 2013; Pattanayak et al., 2013; Cho et al., 2014) , we investigated whether these mutation types were induced by the RGEN system used in this study. The four potential off-target sites most similar to the on-target site in the human genome were searched using the Cas-OFFinder program ( Figure S1D ). We then verified that the RGEN system used in this study did not create any detectable off-target mutations at these sites using the T7E1 assay ( Figure S1E ).
Targeted Genomic Editing of CGG Repeats in Patients' iPSCs and ESCs
To correct FXS in the patients' cells, we utilized our engineered RGENs to edit FXS iPSCs and FXS ESCs. Following electroporation of Cas9 and sgRNA plasmids into WT cells, FXS iPSCs, and FXS ESCs, PCR-based genotyping analysis was performed to screen for edited clones. Of all the edited WT iPSC and WT ESC clones analyzed, only clones with a CGG repeat deletion of approximately 90 bp from their parental lines were selected for further analysis as controls (Table S1 ). In FXS iPSCs and FXS ESCs, we only selected clones that had PCR products of similar size to those of the 90 bp-deleted WT cells ( Figure 1C ). Following the screen and further passaging, two to three edited clones from each cell type with CGG repeat deletions were established out of approximately 100 colonies (2%-3% efficiency) and confirmed using PCR-based genotyping ( Figure 1C ). All edited clones displayed a deletion of the CGG repeat sequence at the 5 0 -UTR of FMR1 ( Figure 1D ). This result demonstrates that targeted DSBs upstream of the CGG repeat are induced by the Cas9 nuclease and can cause large deletions of abnormally mutated repeats. Finally, to verify a complete ablation of the CGG repeats in the selected edited FXS iPSCs, we analyzed our FXS iPSCs as well as the edited FXS iPSC clones E1 and E3 using the AmplideX FMR1 PCR kit. Analysis revealed that, while the parent FXS iPSCs harbored more than 200 repeats, the edited FXS iPSC clones showed no detection of CGGs ( Figure S1F ).
Reactivation of FMR1 Gene Expression in Edited FXS iPSC and FXS NPC Clones
Based on the encouraging results of the genomic DNA editing, we analyzed whether deletion of the CGG repeats would lead to the reactivation of FMR1. To assess the reactivation of the silenced FMR1 gene, mRNA levels were evaluated in WT and FXS iPSCs, in both edited and non-edited isogenic cell lines, using qPCR analysis. Unlike in FXS patient iPSC models, the expression of FMR1 remains active in FXS ESCs, and silencing is sometimes obtained only after a very long differentiation into mature neurons (Urbach et al., 2010) . Because of this difference between patient-derived iPSCs and ESCs, we chose to focus on reactivation of the FMR1 gene by genome editing in the iPSC model system. Interestingly, we found that, in edited FXS iPSCs (FXS iPSC clones E1 and E3), the reactivation of the silenced FMR1 mRNA occurred after deletion of the CGG repeats. We also found that FMR1 mRNA levels were restored to levels similar to those seen in control WT cells. Furthermore, the deletion itself did not show any major change to the transcription of FMR1 in edited WT iPSCs compared with their parental nonedited cells ( Figure 1E ).
To ensure that the reactivation seen in iPSCs is retained through neural differentiation, we induced neural rosettes from WT, FXS-edited, and non-edited isogenic cell lines. No difference in the formation rate of neural rosettes was observed between edited iPSC and ESC lines when compared with their parental lines, indicating that all lines used in the study have a similar potential to differentiate into early neural cells (Figure S2A) . Transcription of FMR1 was maintained in neuronal precursor cells (NPCs) differentiated from all edited FXS iPSC lines (namely, FXS iPSC E1, E2, and E3), with similar expression levels to those seen in WT iPSCs ( Figure 1F ).
Analysis of the Methylation Status within the Promoter Region of FMR1
After successfully reactivating FMR1 at the RNA level, we sought to understand whether the changes seen in expression correlated with epigenetic changes in the promoter region of FMR1. We first analyzed the methylation status of the FMR1 promoter in iPSCs in order to determine whether the deletion of the CGG repeats affected the upstream CpG island of the promoter. Using pyrosequencing, we analyzed 22 CpG sites between À395 to À256 bp from the FMR1 transcription start site (Figure 2A ). The results indicated that, prior to the removal of the CGG repeats in FXS iPSCs by RGEN, all CpG sites were hypermethylated, with most sites reaching 100% methylation ( Figure 2B ). When analyzing the same 22 CpG sites at the FMR1 promoter in our edited FXS iPSC clones, we detected a dramatic demethylation of the promoter, with many CpG sites reaching methylation levels similar to those observed in WT cells ( Figure 2B) . Quantification of the pyrosequencing results showed that the average methylation level of the WT iPSC promoter was 0.4%, and in FXS iPSCs the average promoter methylation reached 87.4%. When analyzing the edited FXS iPSCs, we detected a striking decrease in average methylation of the promoter, which was only 10% in FXS iPSC clone E1 and a mere 0.8% in FXS iPSC clone E3, similar to WT iPSCs ( Figure 2C ).
Methylation levels of the FMR1 promoter also were analyzed in NPCs derived from the aforementioned WT, FXS, edited WT, and edited FXS iPSCs. Similar to what was observed in the iPSCs, NPCs also showed a significant change in promoter methylation levels between edited and non-edited FXS clones. Although both WT NPCs and edited WT NPCs showed hypomethylation, with almost all sites being completely non-methylated, FXS NPCs displayed hypermethylation with most sites reaching close to 100% methylation ( Figure 2B ). In the edited clones, both FXS NPC clones showed clear hypomethylation, with most sites completely unmethylated ( Figure 2B ). Quantification of all sites showed that the average methylation of the FMR1 promoter in WT and edited WT NPCs was 0.2% and 0.7%, respectively (Figure 2C) . In FXS NPCs, average promoter methylation was as high as 87.4%; the average promoter methylation of edited FXS NPCs reached only 0.2% in both clones, similar to the levels observed in WT NPCs ( Figure 2C ).
To analyze changes to the chromatin structure of the FMR1 gene, we employed chromatin immunoprecipitation against histone 3 tail acetylation (H3 Ace) and histone 3 K4 methylation (H3 K4meth), which indicate a transcriptionally active chromatin state, and against histone 3 K9 methylation (H3 K9meth), which indicates a repressed chromatin state and is associated with FMR1 silencing (Coffee et al., 1999 (Coffee et al., , 2002 . Both markers for active chromatin, H3 Ace and H3 K4meth, were markedly upregulated following the CGG repeat editing, and the repressive chromatin marker H3 K9meth was significantly downregulated ( Figure 2D ). In addition, expression levels of APRT, CRYAA, and FMR1 were analyzed in WT and FXS iPSCs using RT-PCR. Expression analysis verified the correlation between expression and epigenetic modifications ( Figure S2B ). These results indicate that the ablation of the CGG repeats had an epigenetic effect on the methylation status and chromatin state of the FMR1 promoter.
Restoration of FMRP Levels in Edited FXS Clones
Lastly, we validated the presence of the FMR1 protein (FMRP), using immunocytochemistry staining in edited iPSC lines as well as their parental lines. As expected, undifferentiated FXS iPSCs stained negative for FMRP, in contrast to WT iPSCs, which stained positive for FMRP ( Figure 3A ). This result was further validated by western blotting to ensure a more sensitive detection of FMRP ( Figure 3B ). In line with our transcription and epigenetic results, we found that the levels of FMRP were restored in the edited FXS iPSC lines E1 and E3. All edited lines showed similar staining of OCT4 compared with their parental lines ( Figure 3A) . Furthermore, other pluripotency markers showed similar expression levels in both edited lines and their parental lines, as detected by qPCR analysis ( Figure S2C ). This result suggests that the procedure leading to the deletion of the repeats did not have a negative effect on the undifferentiated status of the edited clones. Edited ESC lines also were analyzed and showed staining of FMRP similar to that of their isogenic parental ESCs ( Figure S2D ). Next, NPCs derived from FXS iPSC clones E1 and E3 also were analyzed for the presence of FMRP by western blotting, in which they showed high levels of FMRP ( Figure 3C ).
We further examined whether the presence of FMRP could be sustained in mature neurons derived from edited FXS iPSC clones. To address this issue, WT and FXS iPSCs as well as their isogenic edited lines were differentiated into mature neurons (Kim et al., 2010 (Kim et al., , 2012 . We then stained these preparations for FMRP and microtubule-associated protein 2 (MAP2), a mature neuron marker. All differentiated cell lines showed positive staining for MAP2, indicating successful differentiation into mature neurons ( Figure 3D ). Reassuringly, mature neurons differentiated from FXS iPSC clones E1 and E2 stained positive for FMRP, unlike neurons derived from their parental non-edited FXS iPSCs ( Figure 3D ). To investigate any potential effect of the reactivated protein, we analyzed gene expression of edited FXS mature neurons compared with their isogenic parentally derived neurons. Our gene expression analysis demonstrated that, of the few genes that were differentially expressed between edited and non-edited FXS neurons, there was enrichment for different glutamate receptor genes. Several glutamate receptor genes showed more than a 2-fold reduction in RNA levels after editing ( Figure S2E ), whereas other key neuronal genes displayed similar expression levels ( Figure S2F ). This result correlates with a previous study that found dysregulation of glutamate receptor activity in FXS neurons (Dö len et al., 2007) . All together, the results show that genotypic correction generated by deletion of the abnormal repeats can restore FMR1 gene expression and the levels of FMRP in FXS iPSCs and their neural derivatives.
DISCUSSION
Trinucleotide repeat expansions play a role in several neurological, neurodegenerative, and neuromuscular disorders such as Huntington's disease, FXS, spinocerebellar ataxia, and myotonic dystrophy (Pearson et al., 2005) . In FXS, CGG repeat expansion in the 5 0 -UTR of the causative gene FMR1 is linked to the development of the disease phenotype, although the disease mechanisms are not yet fully understood. During the last several years, correction of genetic defects using programmed nucleases has been attempted for several genetic diseases (Yusa et al., 2011; Sebastiano et al., 2011; Yin et al., 2014; Long et al., 2014; Maetzel et al., 2014; Li et al., 2015) . Among these attempts, it has been demonstrated that expanded CAG repeats can be edited in Huntington's disease patient cells using the traditional homologous recombination (HR) or Cas9-mediated HR methods . However, in our study, we attempted a deletion-mediated correction of abnormal CGG repeat expansion without the use of a WT allele or the use of an exogenous donor sequence, but rather through NHEJ induced by the Cas9 nuclease.
Because individuals with less than 55 CGG trinucleotide repeats have normal FMR1 expression and because a lower number of repeats allows for accurate sequencing of repeat portions and their flanking regions, we first tested our deletion-mediated correction approach in WT iPSCs and WT ESCs. As a result, CGG repeats, including some of the flanking regions, were successfully deleted in the WT cells. We then applied this approach to FXS patients' iPSCs and ESCs and succeeded in restoring FMR1 expression. No difference was observed in the ability of edited cell lines to differentiate into NPCs and mature neurons when compared to the abilities of their parental cell lines.
In our sequencing analysis, we frequently observed deletions in corrected iPSC/ESC lines as well as in RGEN-transfected HEK293T cells. We speculate that some of these deletions may have been induced by microhomology-mediated end joining (MMEJ) that can cause variable-size deletions by base pairing between two short microhomologous sequences near the DSB region created by the engineered nucleases (McVey and Lee, 2008; Bae et al., 2014b) . Our hypothesis that some deletions may have been caused by MMEJ is supported by the fact that numerous GC repeats were found in the upstream and downstream regions of CGG repeats, and by the fact that microhomologous sequences such as GGC and CGG were observed on both sides of the deletion in the case of 49-and 112-bp deletions ( Figure S1C ). Other deletions and insertions in general may have been induced by NHEJ.
The results of this study showed the reactivation of FMR1 at the RNA, methylation, chromatin modification, and protein levels. Taking our current findings together with our previous results (Urbach et al., 2010; Eiges et al., 2007; Bar-Nur et al., 2012) , we propose a model in which the presence of more than 200 CGG repeats is necessary, but not sufficient, for the silencing of FMR1. The presence of the full mutation is recognized during differentiation as a site for DNA methyltransferase activity, leading to full methylation of the CGG repeats. These epigenetic changes spread to the upstream and cause both DNA methylation of the CpG island at the FMR1 promoter and the closed chromatin conformation in this region. In this work, we clearly demonstrate that removal of the CGG repeats in undifferentiated cells can lead to demethylation of the promoter, open chromatin conformation, and re-expression of the gene, all of which are sustained through neural rosette formation and long-term differentiation into mature neurons. These findings suggest a maintenance mechanism in which the methylation status of the promoter is constantly regulated according to the state of the repeats. Thus, when the repeats are removed, the FMR1 promoter loses its methylation and shows an upregulation of active chromatin markers, thereby activating the FMR1 gene ( Figures 2D and 4) .
The data presented demonstrate the ablation of full-mutation trinucleotide repeats and the complete reactivation of a gene using Cas9 nuclease without the use of a donor sequence for HR. Our Cas9-mediated method to correct trinucleotide repeats may be applied on patient-specific cells for gene correction of various short nucleotide repeat expansion-derived diseases, such as spinocerebellar ataxia and myotonic dystrophy. Further work on edited FXS iPSCs should be done to understand the full impact of the reactivation of FMRP and may reveal yet unknown functions of this important protein. This method for gene correction can be applied easily in many labs and holds a great potential for the study of trinucleotide repeat disorders as well as future research for novel therapies. In FXS iPSCs, FMR1 is silenced because of the presence of the full mutation of CGG repeats and their methylation, which affects the gene's promoter. After removal of the CGG repeats by RGEN, the promoter is released from its repressive markers and is completely demethylated. Demethylation of the FMR1 promoter allows the gene to be transcribed and, hence, FMR1 is reactivated.
EXPERIMENTAL PROCEDURES
Cas9-Encoding Plasmid and Transfections
Cas9 and sgRNA expression plasmids were purchased from ToolGen. Potential off-target sites were computationally searched using Cas-OFFinder (http://www.rgenome.net/; Bae et al., 2014a) . Human iPSCs and ESCs were pulsed with Cas9 and sgRNA-encoding plasmids as previously described (Park et al., 2014) .
Isolation of Clonal Cells and PCR Analysis
To isolate clonal populations of edited cells, each colony that had been identified by PCR with a deletion in the CGG repeats was dissociated into single cells and re-seeded onto a new feeder layer as previously described (Park et al., 2014) .
DNA Methylation Analysis
For DNA methylation analysis, genomic DNA was purified using the NucleoSpin Tissue kit (Macherey-Nagel) according to the manufacturer's protocol. Pyrosequencing was performed by EpigenDx according to standard procedures, with a unique set of primers developed by EpigenDx for targeting 22 CpG sites at the FMR1 promoter.
Chromatin Immunoprecipitation
For chromatin immunoprecipitation, FXS and edited FXS iPSCs were harvested, fixated, and cross-linked with formaldehyde solution, lysed, and sonicated. Chromatin was cleared using salmon sperm agarose beads (Millipore) for 1 hr at 4 C. Immunoprecipitation of chromatin was performed overnight using an anti-acetylated histone H3 antibody (Millipore 06599), an anti-methylated histone H3 at lysine 4 antibody (Millipore 17614), and an anti-methylated histone H3 at lysine 9 antibody (Millipore 17648). For more detailed information, see the Supplemental Experimental Procedures. 
SUPPLEMENTAL INFORMATION
Supplemental Information includes
